There's no guarantee that any stock is completely unstoppable. However, three Motley Fool contributors think they've identified some that come close. Here's why they picked Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and Vertex Pharmaceuticals (NASDAQ: VRTX).

Keith Speights (Eli Lilly): Over the last 12 months, Eli Lilly's shares have skyrocketed close to 80% higher. Along the way, the company became the biggest drugmaker in the world based on market cap. I look for Lilly to keep its momentum going in 2024.

Lilly's lineup already included huge winners such as type 2 diabetes drugs Jardiance and Mounjaro, autoimmune disease drugs Olumiant and Taltz, and breast cancer drug Verzenio going into 2023. But in November, the company added what is likely to become its most successful product ever with the U.S. Food and Drug Administration's approval of Zepbound for chronic weight management.

Continue reading

Source Fool.com